CMC Biologics adds capacity to GMP manufacturing facility in Denmark
Bioreactor 6Pack facility design provides flexible solutions for Phase III and commercial production
CMC Biologics, a manufacturer of therapeutic proteins, will add approximately 14,000 litres of additional manufacturing capacity to its facility in Copenhagen, Denmark.
Scheduled for initial GMP production in November this year, the installation will include a Bioreactor 3Pack configuration consisting of a seed train and three 2,000 L single-use production bioreactors. Three additional 2,000 L bioreactors will be added later.
The company has already installed a Bioreactor 6Pack in its US facility in Seattle and will conduct the first GMP run there by the middle of this year, with full production for a commercial launch later.
Gustavo Mahler, Global Chief Operations Officer of CMC Biologics, said the company is making a major investment in innovative facility design to address customers' needs for production flexibility, and to meet aggressive regulatory and production timelines and to speed products to market.
'We are changing the way CMOs operate and our novel Bioreactor 6Pack facility design is one more step in leading the market in technical excellence,' he said.